

Manish Kumar Jha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3719116/publications.pdf>

Version: 2024-02-01

130
papers

2,807
citations

218677

26
h-index

214800

47
g-index

144
all docs

144
docs citations

144
times ranked

3292
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders. <i>Neuropsychopharmacology</i> , 2022, 47, 420-421.	5.4	2
2	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2022, 91, 550-560.	1.3	9
3	Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?. <i>Molecular Psychiatry</i> , 2022, 27, 1095-1102.	7.9	52
4	A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients. <i>General Hospital Psychiatry</i> , 2022, 74, 1-8.	2.4	5
5	Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 85-88.	2.1	4
6	Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory. <i>Translational Psychiatry</i> , 2022, 12, 16.	4.8	5
7	Quantification of brain age using high-resolution 7 tesla MR Imaging and implications for epilepsy. <i>Epilepsy and Behavior Reports</i> , 2022, 18, 100530.	1.0	0
8	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 149, 243-251.	3.1	4
9	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 20-28.	1.5	6
10	Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study. <i>Depression and Anxiety</i> , 2021, 38, 57-66.	4.1	7
11	Quality of life after response to acute-phase cognitive therapy for recurrent depression. <i>Journal of Affective Disorders</i> , 2021, 278, 218-225.	4.1	6
12	Design and rationale of an intelligent algorithm to detect BuRnoUt in Healthcare workers in COVID era using ECG and artificial intelligence: The BRUCEE-LI study. <i>Indian Heart Journal</i> , 2021, 73, 109-113.	0.5	10
13	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 151-157.	4.3	6
14	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2021, 35, 124-127.	4.0	2
15	Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome. <i>Psychiatric Quarterly</i> , 2021, 92, 1069-1077.	2.1	0
16	Sex-specific differences in the association between body mass index and brain aging in young adults: Findings from the human connectome project. <i>Psychoneuroendocrinology</i> , 2021, 124, 105059.	2.7	8
17	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , 2021, 178, 193-202.	7.2	122
18	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 602-610.	4.1	3

#	ARTICLE	IF	CITATIONS
19	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	6
20	Neurocircuit Mechanisms of Active Suicidal Ideation in Youths and Young Adults: Findings From the T-Rad Study. <i>Biological Psychiatry</i> , 2021, 89, S82.	1.3	0
21	Functional Neuroimaging Moderators of Improvement in Irritability With Antidepressants vs. Placebo in Adults With Major Depressive Disorder: Findings From the EMBARC Study. <i>Biological Psychiatry</i> , 2021, 89, S47.	1.3	0
22	Association Between Habenular Volume and Hemoglobin A1c in Young Adults Differs on the Basis of Smoking Status: Findings From the Human Connectome Project. <i>Biological Psychiatry</i> , 2021, 89, S271-S272.	1.3	0
23	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 437-446.	7.2	33
24	Whole-Transcriptome Brain Expression and Exon-Usage Profiling in Major Depression and Suicide. <i>Biological Psychiatry</i> , 2021, 89, S120-S121.	1.3	0
25	Irritability Partly Accounts for the Association Between Pain and Depression: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project. <i>Biological Psychiatry</i> , 2021, 89, S91.	1.3	0
26	Sex-Specific Differences in the Association Between Obesity and Depression in Large Epidemiological Studies: Findings From Dallas Heart Study and National Health and Nutrition Examination Survey. <i>Biological Psychiatry</i> , 2021, 89, S340.	1.3	0
27	Vortioxetine Versus Placebo for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	16
28	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. <i>Neuropsychopharmacology</i> , 2021, 46, 2266-2277.	5.4	19
29	Smoking status links habenular volume to glycated hemoglobin: Findings from the Human Connectome Project-Young Adult. <i>Psychoneuroendocrinology</i> , 2021, 131, 105321.	2.7	4
30	Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study. <i>Journal of Affective Disorders</i> , 2021, 292, 108-113.	4.1	5
31	Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study. <i>Journal of Psychiatric Research</i> , 2021, 142, 258-262.	3.1	10
32	COVID 19-related burnout among healthcare workers in India and ECG based predictive machine learning model: Insights from the BRUCEE- Li study. <i>Indian Heart Journal</i> , 2021, 73, 674-681.	0.5	10
33	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	7.9	235
34	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. <i>American Journal of Psychiatry</i> , 2020, 177, 143-154.	7.2	76
35	Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior. <i>Psychoneuroendocrinology</i> , 2020, 111, 104487.	2.7	26
36	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2020, 77, 397.	11.0	45

#	ARTICLE	IF	CITATIONS
37	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). <i>Journal of Psychiatric Research</i> , 2020, 122, 22-32.	3.1	21
38	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. <i>International Clinical Psychopharmacology</i> , 2020, 35, 313-321.	1.7	9
39	Neural Correlates of Irritability and Suicidality in Adult Outpatients With Major Depressive Disorder: Findings From the EMBARC Study. <i>Biological Psychiatry</i> , 2020, 87, S312.	1.3	0
40	Irritability as an Independent Predictor of Suicidality: Findings From Four Clinical Trials of Adults With Either Major Depressive Disorder or Stimulant Use Disorder. <i>Biological Psychiatry</i> , 2020, 87, S73.	1.3	0
41	Sex Differences in Dysfunctional Th2 Immune Response With Suicidality. <i>Biological Psychiatry</i> , 2020, 87, S336-S337.	1.3	0
42	Association of Anger Attacks With Persistently Elevated Suicidality in Depressed Patients: Do Early Improvements in Irritability Reduce the Risk?. <i>Biological Psychiatry</i> , 2020, 87, S108-S109.	1.3	0
43	Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study. <i>Psychiatric Research and Clinical Practice</i> , 2020, 2, 10-18.	2.4	7
44	Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 2147-2154.	5.4	26
45	Neural Circuits Linking Irritability and Anger Attacks in Major Depressive Disorder: Findings From EMBARC Study. <i>Biological Psychiatry</i> , 2020, 87, S72.	1.3	0
46	Childhood maltreatment and impact on clinical features of major depression in adults. <i>Psychiatry Research</i> , 2020, 293, 113412.	3.3	26
47	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. <i>Journal of Affective Disorders</i> , 2020, 277, 478-485.	4.1	4
48	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2020, 126, 19-25.	3.1	14
49	Pharmacological Treatments for Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2020, 13, 116.	3.8	78
50	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. <i>Depression and Anxiety</i> , 2020, 37, 771-783.	4.1	22
51	Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. <i>Psychological Medicine</i> , 2020, , 1-9.	4.5	6
52	Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study. <i>Journal of Affective Disorders</i> , 2020, 275, 44-47.	4.1	9
53	An electroencephalographic signature predicts antidepressant response in major depression. <i>Nature Biotechnology</i> , 2020, 38, 439-447.	17.5	157
54	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. <i>Depression and Anxiety</i> , 2020, 37, 485-495.	4.1	9

#	ARTICLE	IF	CITATIONS
55	180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. <i>CNS Spectrums</i> , 2020, 25, 313-314.	1.2	0
56	What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	10
57	Efficacy of Esketamine Augmentation in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	71
58	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	2.2	6
59	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. <i>Psychological Medicine</i> , 2019, 49, 1118-1127.	4.5	109
60	F143. Do Age and Sex Moderate the Association of Inflammatory Cytokines and Anhedonia in Major Depressive Disorder? Findings From CO-MED Trial. <i>Biological Psychiatry</i> , 2019, 85, S268.	1.3	0
61	Differential prediction of antidepressant treatment response via measurement of baseline adiponectin level: findings from the CO-MED randomized clinical trial. <i>Journal of Affective Disorders</i> , 2019, 254, 132-133.	4.1	0
62	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. <i>Annals of Family Medicine</i> , 2019, 17, 326-335.	1.9	32
63	224. Sex Differences in Association of Inflammation and Suicidality: Findings From Two Separate Cohorts of Patients With Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S93.	1.3	0
64	S90. Association of Autoimmunity With Dysfunctional Th2-Mediated Immune Response in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S331-S332.	1.3	0
65	133. Baseline Functional Connectivity and Cerebral Perfusion Markers of Response to Sertraline Vs. Placebo: A Data-Driven Multi-Modal Neuroimaging Study. <i>Biological Psychiatry</i> , 2019, 85, S55-S56.	1.3	0
66	O14. Cerebral Blood Perfusion Predicts Response to Antidepressant Treatment in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S111.	1.3	0
67	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. <i>Nature Human Behaviour</i> , 2019, 3, 1319-1331.	12.0	29
68	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. <i>Journal of Psychopharmacology</i> , 2019, 33, 185-193.	4.0	14
69	VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. <i>Pharmaceuticals</i> , 2019, 12, 71.	3.8	33
70	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. <i>EClinicalMedicine</i> , 2019, 10, 32-41.	7.1	19
71	57. Dysfunctional Th2-Cell Mediated Adaptive Immune Response is Associated With Suicide Behavior in Adolescents and Young Adults. <i>Biological Psychiatry</i> , 2019, 85, S24.	1.3	0
72	When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor. <i>American Journal of Psychiatry</i> , 2019, 176, 488-489.	7.2	4

#	ARTICLE	IF	CITATIONS
73	Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth. <i>JAMA Psychiatry</i> , 2019, 76, 766.	11.0	0
74	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 339-348.	2.1	7
75	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2019, 113, 165-171.	3.1	33
76	Screening and Management of Depression in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1827-1845.	2.8	182
77	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. <i>American Journal of Psychiatry</i> , 2019, 176, 358-366.	7.2	39
78	Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program. <i>International Journal for Quality in Health Care</i> , 2019, 31, 57-63.	1.8	13
79	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. <i>Focus (American J Psychiatry)</i> , 2019, 117, 107-114.	0.8	1
80	Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial. <i>Pharmaceuticals</i> , 2019, 12, 184.	3.8	10
81	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. <i>Journal of Affective Disorders</i> , 2019, 242, 87-95.	4.1	14
82	Anti-Inflammatory Treatments for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	6
83	Discontinuing Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	6
84	Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. <i>Journal of Affective Disorders</i> , 2018, 234, 34-37.	4.1	50
85	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. <i>Journal of Affective Disorders</i> , 2018, 235, 45-51.	4.1	32
86	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2018, 102, 207-215.	3.1	12
87	154. Gender-Specific Association of IL-17 with Anhedonia in Depressed Outpatients: Findings From CO-MED Trial. <i>Biological Psychiatry</i> , 2018, 83, S63.	1.3	0
88	A pilot program for implementing mental health screening, assessment, and navigation in a community-based cancer center. <i>Psycho-Oncology</i> , 2018, 27, 683-686.	2.3	5
89	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. <i>Journal of Affective Disorders</i> , 2018, 233, 3-14.	4.1	116
90	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018, 11, 75-84.	1.6	20

#	ARTICLE	IF	CITATIONS
91	5.68 Factors Related to Disorganized Attachment Style of Trauma-Affected Young Children in a Therapeutic Daycare Setting. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, S249.	0.5	0
92	156. Inflammation Selectively Impairs Executive Function in Treatment-Resistant Depressed Outpatients: Findings From TREAD Study. <i>Biological Psychiatry</i> , 2018, 83, S63-S64.	1.3	0
93	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. <i>American Journal of Psychiatry</i> , 2018, 175, 1176-1184.	7.2	47
94	Pharmacogenomics and Biomarkers of Depression. <i>Handbook of Experimental Pharmacology</i> , 2018, 250, 101-113.	1.8	11
95	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. <i>Molecular Neuropsychiatry</i> , 2018, 4, 7-19.	2.9	12
96	Association of T and non-T cell cytokines with anhedonia: Role of gender differences. <i>Psychoneuroendocrinology</i> , 2018, 95, 1-7.	2.7	34
97	68. Blood Brain Barrier Dysfunction Selectively Predicts Poorer Outcomes With SSRI Monotherapy vs. Antidepressant Combinations: Clinical Utility of Novel Astrocytic Marker. <i>Biological Psychiatry</i> , 2018, 83, S28.	1.3	1
98	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. <i>Personalized Medicine in Psychiatry</i> , 2018, 9-10, 1-7.	0.1	5
99	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 325-332.	2.1	27
100	Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 233.	4.1	60
101	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 285-295.	8.8	39
102	Experimental Therapies for Treatment-Resistant Depression: Deciding When to Go to an Unproven or Experimental Therapy. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 279-284.	0.8	4
103	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. <i>Neuropsychopharmacology</i> , 2018, 43, 2197-2203.	5.4	12
104	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. <i>Psychoneuroendocrinology</i> , 2017, 78, 105-113.	2.7	155
105	Is C-reactive protein ready for prime time in the selection of antidepressant medications?. <i>Psychoneuroendocrinology</i> , 2017, 84, 206.	2.7	16
106	Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. <i>Journal of Psychiatric Research</i> , 2017, 94, 1-6.	3.1	23
107	317. Screening for Auto-Antibodies with Antidepressant Medications Using Glomerular Proteomic Microarray Arrays: Findings from CoMed Clinical Trial. <i>Biological Psychiatry</i> , 2017, 81, S130-S131.	1.3	1
108	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. <i>Brain, Behavior, and Immunity</i> , 2017, 66, 103-110.	4.1	60

#	ARTICLE	IF	CITATIONS
109	1.5 Factors Impacting the Resilience of Trauma-Affected Young Children in a Therapeutic Daycare Setting. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, S153-S154.	0.5	0
110	Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 919-927.	2.1	29
111	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 3001-3010.	2.2	3
112	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 803-813.	2.2	21
113	Implementing mental health screening, assessment, and navigation program in a community-based survivorship program.. <i>Journal of Clinical Oncology</i> , 2017, 35, 36-36.	1.6	1
114	Teaching Motivational Interviewing Skills to Psychiatry Trainees: Findings of a National Survey. <i>Academic Psychiatry</i> , 2016, 40, 149-152.	0.9	6
115	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1036-1042.	2.2	15
116	Commentary: Clinical Approach to the Differential Diagnosis between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2016, 7, 23.	2.6	0
117	IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. <i>Depression and Anxiety</i> , 2016, 33, 870-881.	4.1	31
118	3.50 STUDY OF TRAUMA-AFFECTED YOUNG CHILDREN IN A THERAPEUTIC DAYCARE SETTING. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S158.	0.5	0
119	Attitudes Towards Substance Use Disorders and Association with Motivational Interviewing Education: A Survey of Psychiatry Chief Residents. <i>Academic Psychiatry</i> , 2016, 40, 523-524.	0.9	2
120	COMT val158met polymorphism and molecular alterations in the human dorsolateral prefrontal cortex: Differences in controls and in schizophrenia. <i>Schizophrenia Research</i> , 2016, 173, 94-100.	2.0	8
121	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 1196-1204.	7.2	40
122	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. <i>Journal of Affective Disorders</i> , 2016, 206, 17-22.	4.1	26
123	Altered GABA neurotransmission in major depressive disorder: Re-analyzing publicly available data. <i>European Neuropsychopharmacology</i> , 2016, 26, 796.	0.7	2
124	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. <i>PLoS ONE</i> , 2016, 11, e0167901.	2.5	26
125	A Case of Frontotemporal Dementia Presenting With Treatment-Refractory Psychosis and Extreme Violence. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 732-733.	1.4	10
126	Training Psychiatry Residents at Correctional Facilities. <i>Academic Psychiatry</i> , 2015, 39, 123-124.	0.9	2

#	ARTICLE	IF	CITATIONS
127	Availability and Attitudes Toward Correctional Psychiatry Training: Results of a National Survey of Training Directors. <i>Journal of Behavioral Health Services and Research</i> , 2014, 41, 244-250.	1.4	9
128	Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 167, 37-43.	4.1	14
129	Can We Address the Shortage of Psychiatrists in the Correctional Setting with Exposure During Residency Training?. <i>Community Mental Health Journal</i> , 2012, 48, 756-760.	2.0	11
130	Post adoption depression. <i>Archives of Women's Mental Health</i> , 2010, 13, 147-151.	2.6	34